Trial Profile
A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Subjects With Chronic Genotype 3 HCV Infection and Cirrhosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Mar 2019
Price :
$35
*
At a glance
- Drugs Sofosbuvir/velpatasvir (Primary) ; Sofosbuvir/velpatasvir/voxilaprevir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms POLARIS-3
- Sponsors Gilead Sciences
- 13 Nov 2018 Integrated analysis results of pooled data presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases
- 01 Oct 2018 Results of a pooled analysis assessing patients reported outcomes from 11 studies, published in the Value in Health.
- 05 Dec 2017 Results of resistance analysis in HCV infected patients Genotype 1-6 from phase III studies (ASTRAL-1, ASTRAL-2, ASTRAL-3, ASTRAL-5 and POLARIS-2, POLARIS-3; n=1778) published in the Journal of Hepatology